Skip to main content

Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology–Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients

Abstract

Purpose of Review

Diagnosis and treatment of psoriatic arthritis (PsA) can be challenging and require a multidisciplinary approach. This review provides an overview of combined dermatology–rheumatology clinics.

Recent Findings

Combined dermatology–rheumatology clinics have emerged to optimize integrated care for patients with psoriasis and PsA. There are over 20 such clinics across the USA. These clinics facilitate multidisciplinary care for patients with psoriasis and PsA and have been found to improve outcomes and enhance both patient and physician satisfaction and knowledge. Challenges presented by these clinics include appropriate scheduling for both dermatologists and rheumatologists and proving the benefits of the clinics to obtain institutional support.

Summary

Combined dermatology–rheumatology clinics are a novel model of care for patients with psoriasis and PsA. They improve outcomes, patient and physician satisfaction, and efficiency. As more of these clinics are established, we must further understand their impact on outcomes and care processes.

This is a preview of subscription content, access via your institution.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352:1899–912.

    CAS  Article  PubMed  Google Scholar 

  2. Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26:314–20.

    CAS  Article  PubMed  Google Scholar 

  3. Boehncke W-H, Dressel D, Zollner TM, Kaufmann R. Pulling the trigger on psoriasis. Nature. 1996;379:777.

    CAS  Article  PubMed  Google Scholar 

  4. Christophers E. The immunopathology of psoriasis. Int Arch Allergy Immunol. 1996;110:199–206.

    CAS  Article  PubMed  Google Scholar 

  5. Mueller W, Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979;301(10):555.

    CAS  PubMed  Google Scholar 

  6. Schon MP, Detmar M, Parker CM. Murine psoriasis-like disorder induced by naive CD4+ T-cells. Nat Med. 1997;3:183–8.

    CAS  Article  PubMed  Google Scholar 

  7. Wrone-Smith T, Nickoloff BJ. Dermal injection of immunocytes induces psoriasis. J Clin Invest. 1996;98:1878–87.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. Soleymani T, Hung T, Soung J. The role of vitamin D in psoriasis: a review. Int J Dermatol. 2015;54(4):383–92. https://doi.org/10.1111/ijd.12790.

    CAS  Article  PubMed  Google Scholar 

  9. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005;64 Suppl 2:ii30–6.

    CAS  PubMed  Google Scholar 

  10. Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145–154.e9. https://doi.org/10.1016/j.jaci.2012.04.024.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S67–80.

    Article  PubMed  Google Scholar 

  12. • Lynde CW, Poulin Y, Vender R, Bourcier M, Khalil S. Interleukin 17A: toward a new understanding of psoriasis pathogenesis. J Am Acad Dermatol. 2014;71(1):141–50. https://doi.org/10.1016/j.jaad.2013.12.036. Overview of the current understanding of psoriasis pathophysiology.

    CAS  Article  PubMed  Google Scholar 

  13. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133–41.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  14. Baeten DL, Kuchroo VK. How cytokine networks fuel inflammation: Interleukin-17 and a tale of two autoimmune diseases. Nat Med. 2013;19(7):824–5. https://doi.org/10.1038/nm.3268.

    CAS  Article  PubMed  Google Scholar 

  15. Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–90. https://doi.org/10.1016/j.jaad.2016.07.064.

    Article  PubMed  Google Scholar 

  16. • Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41:545–68. Good overview of psoriatic arthritis epidemiology and brief pathophysiology.

    Article  Google Scholar 

  17. Ogdie A, Langan S, Love T, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford). 2013;52:568–75.

    Article  Google Scholar 

  18. • Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729–35. Good overview on difference in PsA epidemiology as seen by rheumatologists.

    Article  PubMed  Google Scholar 

  19. Li R, Sun J, Ren LM, et al. Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing. Rheumatology (Oxford). 2012;51:721–9.

    Article  Google Scholar 

  20. Yang Q, Qu L, Tian H, et al. Prevalence and characteristics of psoriatic arthritis in Chinese patients with psoriasis. J Eur Acad Dermatol Venereol. 2011;25:1409–14.

    CAS  Article  PubMed  Google Scholar 

  21. Carneiro JN, Paula AP, Martins GA. Psoriatic arthritis in patients with psoriasis: evaluation of clinical and epidemiological features in 133 patients followed at the University Hospital of Brasília. An Bras Dermatol. 2012;87:539–44.

    Article  PubMed  Google Scholar 

  22. Henes JC, Ziupa E, Eisfelder M, et al. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study. Rheumatol Int. 2014;34:227–34.

    CAS  Article  PubMed  Google Scholar 

  23. Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009;61:1373–8.

    CAS  Article  PubMed  Google Scholar 

  24. Jamshidi F, Bouzari N, Seirafi H, et al. The prevalence of psoriatic arthritis in psoriatic patients in Tehran, Iran. Arch Iran Med. 2008;11:162–5.

    PubMed  Google Scholar 

  25. Love TJ, Gudbjornsson B, Gudjonsson JE, et al. Psoriatic arthritis in Reykjavik, Iceland: prevalence, demographics, and disease course. J Rheumatol. 2007;34:2082–8.

    PubMed  Google Scholar 

  26. Haroon M, Kirby B, FitzGerald O. High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires. Ann Rheum Dis. 2013;72:736–40.

    Article  PubMed  Google Scholar 

  27. Love TJ, Gudjonsson JE, Valdimarsson H, et al. Psoriatic arthritis and onycholysis—results from the cross-sectional Reykjavik psoriatic arthritis study. J Rheumatol. 2012;39:1441–4.

    Article  PubMed  Google Scholar 

  28. Khraishi M, Chouela E, Bejar M, et al. High prevalence of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice. J Cutan Med Surg. 2012;16:122–7.

    PubMed  Google Scholar 

  29. Radtke MA, Reich K, Blome C, et al. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol. 2009;23:683–91.

    CAS  Article  PubMed  Google Scholar 

  30. Reich K, Kruger K, Mossner R, et al. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160:1040–7.

    CAS  Article  PubMed  Google Scholar 

  31. Tey HL, Ee HL, Tan AS, et al. Risk factors associated with having psoriatic arthritis in patients with cutaneous psoriasis. J Dermatol. 2010;37:426–30.

    Article  PubMed  Google Scholar 

  32. Ficco HM, Citera G, Cocco JA. Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria. Clin Rheumatol. 2014;33:1489–93.

    Article  PubMed  Google Scholar 

  33. Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. Raposo I, Torres T. Nail psoriasis as a predictor of the development of psoriatic arthritis. Actas Dermosifiliogr. 2015;106:452–7.

    CAS  Article  PubMed  Google Scholar 

  35. Merola JF, Wu S, Han J, et al. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis. 2015;74:1495–500.

    Article  PubMed  Google Scholar 

  36. Mody E, Husni ME, Schur P, et al. Multidisciplinary evaluation of patients with psoriasis presenting with musculoskeletal pain: a dermatology: rheumatology clinic experience. Br J Dermatol. 2007;157:1050–1.

    CAS  Article  PubMed  Google Scholar 

  37. Marchesoni A, Atzeni F, Spadaro A, et al. Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol. 2012;39:849–55.

    Article  PubMed  Google Scholar 

  38. De Marco G, Cattaneo A, Battafarano N, et al. Not simply a matter of psoriatic arthritis: epidemiology of rheumatic diseases in psoriatic patients. Arch Dermatol Res. 2012;304:719–26.

    Article  PubMed  Google Scholar 

  39. Tan AL, Grainger AJ, Tanner SF, et al. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum. 2006;54:1328–33.

    Article  PubMed  Google Scholar 

  40. Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol. 2015;73:242–8.

    Article  PubMed  Google Scholar 

  41. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14–7.

    CAS  PubMed  Google Scholar 

  42. • Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;73:423–41. Great overview on management of psoriatic patients with PsA.

    Article  Google Scholar 

  43. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851–64. https://doi.org/10.1016/j.jaad.2008.02.040.

    Article  PubMed  Google Scholar 

  44. •• Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70:2152–4. Important study demonstrating early intervention may herald better outcomes.

    Article  PubMed  Google Scholar 

  45. •• Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73:407–13. Registry study demonstrating early intervention heralds optimal outcomes.

    Article  PubMed  Google Scholar 

  46. Van De Kerkhof P, Nestle FO. "Chapter 8: Psoriasis." Dermatology, 3rd ed. Ed. Jean L Bolognia, Ed. Joseph L. Jorrizo, Ed. Julie V. Schaffer. Elsevier/Saunders, 2012. 135-156.

  47. Khraishi M, Landells I, Mugford G. The self-administered Psoriasis and Arthritis Screening Questionnaire (PASQ): a sensitive and specific tool for the diagnosis of early and established psoriatic arthritis. Psoriasis Forum. 2010;16:9–16.

    Google Scholar 

  48. Ibrahim GH, Buch MH, Lawson C, Waxman R, Helliwell PS. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27:469–74.

    CAS  PubMed  Google Scholar 

  49. Gladman DD, Schentag CT, Tom BDM, Chandran V, Brockbank J, Rosen C, et al. Development and initial validation of a screening questionnaire for psoriatic arthritis: the Toronto Psoriatic Arthritis Screen (ToPAS). Ann Rheum Dis. 2009;68:497–501.

    CAS  Article  PubMed  Google Scholar 

  50. Husni ME, Meyer KH, Cohen DS, Mody E, Qureshi AA. The PASE questionnaire: pilot testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57(4):581–7.

    Article  PubMed  Google Scholar 

  51. Coates LC, Aslam T, Al Balushi F, Burden AD, Burden-Teh E, Caperon AR, et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol. 2013;168(4):802–7. https://doi.org/10.1111/bjd.12190.

    CAS  Article  PubMed  Google Scholar 

  52. •• Okhovat JP, Ogdie A, Reddy SM, Rosen CF, Scher JU, Merola JF. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: benefits and challenges of combined rheumatology-dermatology clinics. J Rheumatol. 2017;44:693–4. https://doi.org/10.3899/jrheum.170148. Seminal study demonstrating benefits and challenges to combined clinics.

    Article  PubMed  Google Scholar 

  53. Helliwell PS, Gladman DD, Gottlieb AB. Prologue: 2016 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). J Rheumatol. 2017;44(5):658–60. https://doi.org/10.3899/jrheum.170139.

    Article  PubMed  Google Scholar 

  54. Jadon DR, Gladman DD, Mease PJ, et al. Proceedings of the GRAPPA 2016 retreat. J Rheumatol. 2017;44(5):668–73. https://doi.org/10.3899/jrheum.170141.

    Article  PubMed  Google Scholar 

  55. McNamara, Damien. “Conference Coverage from the 2016 GRAPPA annual meeting—benefits, challenges emerge in evolution of rheumatology-dermatology clinics.” Dermatology News 21 July 2016: Web. http://www.mdedge.com/edermatologynews/article/110512/psoriasis/benefits-challenges-emerge-evolution-rheumatology.

  56. Gallegos, Alicia. “Combined dermatology-rheumatology clinics improve care, Spark New Research.” Dermatology News 16 Oct. 2015: Web. http://www.mdedge.com/edermatologynews/article/103593/psoriatic-arthritis/combined-dermatology-rheumatology-clinics.

  57. Velez NF, Wei-Passanese EX, Husni ME, Mody EA, Qureshi AA. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch Dermatol Res. 2012;304(1):7–13. https://doi.org/10.1007/s00403-011-1172-6.

    Article  PubMed  Google Scholar 

  58. • Luelmo J, Gratacos J, Martinez-Losa MM, et al. A report of 4 years of experience of a multidisciplinary unit of psoriasis and psoriatic arthritis. Reumatol Clin. 2014;10(3):141–6. Longitudinal study on the multidisciplinary experience in patients with psoriasis and psoriatic arthritis.

    Article  PubMed  Google Scholar 

  59. Pérez-Barrio S, Galíndez E, Alzaga JMC, García-Vivar ML, Urigoitia P, Belloso RI. Psoriasis and psoriatic arthropathy multidisciplinary clinic at Basurto University Hospital: 2 years of experience. J Am Acad Dermatol. 2014;70(5):AB180.

    Google Scholar 

  60. Gratacos-Masmitja J, Luelmo-Aguilar J, Zarco-Montejo P, Botella-Estrada R, Carrizosa-Esquivel AM, Garcia-Vivar ML, et al. Points to consider in the foundation of multidisciplinary units for psoriatic arthritis: a Delphi study and a systematic review of the literature. Adv Ther. 2017;33(12):2150–9.

    Article  PubMed  Google Scholar 

  61. •• Cobo-Ibáñez T, Villaverde V, Seoane-Mato D, Muñoz-Fernández S, Guerra M, Del Campo PD, et al. Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatol Int. 2016;36(2):221–9. https://doi.org/10.1007/s00296-015-3377-z. Important systematic review investigating the benefits and challenges of combined multidisciplinary clinics for patients with psoriasis and psoriatic arthritis.

    Article  PubMed  Google Scholar 

  62. Samycia M, McCourt C, Shojania K, Au S. Experiences from a combined dermatology and rheumatology clinic: a retrospective review. J Cutan Med Surg. 2016;20(5):486–9. https://doi.org/10.1177/1203475416649138.

    Article  PubMed  Google Scholar 

  63. Samycia M, et al. Paper #2937. Presented at: American Academy of Dermatology 74th Annual Meeting; March 4–8, 2016; Washington, D.C.

  64. Ash Z, Gaujoux-Viala C, Gossec L, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and metaanalysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71:319–26.

    CAS  Article  PubMed  Google Scholar 

  65. Yamamoto M, et al. Psoriatic inflammation facilitates the onset of arthritis in a mouse model. J Investig Dermatol. 2015;135:445–53.

    CAS  Article  PubMed  Google Scholar 

  66. Nograles K, et al. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol. 2009;5(2):83–91.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  67. Griffiths CE, Strober BE, van de Kerkhof P, Ho V, Fidelus-Gort R, Yeilding N, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362(2):118–28. https://doi.org/10.1056/NEJMoa0810652.

    CAS  Article  PubMed  Google Scholar 

  68. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  69. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–89.

    CAS  Article  PubMed  Google Scholar 

  70. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–72.

    CAS  Article  PubMed  Google Scholar 

  71. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349(21):2014–22.

    CAS  Article  PubMed  Google Scholar 

  72. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158(3):558–66.

    CAS  Article  PubMed  Google Scholar 

  73. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58(1):106–15.

    Article  PubMed  Google Scholar 

  74. Chan SA, Hussain F, Lawson LG, Ormerod AD. Factors affecting adherence to treatment of psoriasis: comparing biologic therapy to other modalities. J Dermatolog Treat. 2013;24(1):64–9. https://doi.org/10.3109/09546634.2011.607425.

    CAS  Article  PubMed  Google Scholar 

  75. Gokdemir G, Ari S, Koslu A. Adherence to treatment in patients with psoriasis vulgaris: Turkish experience. J Eur Acad Dermatol Venereol. 2008;22:330–5.

    CAS  Article  PubMed  Google Scholar 

  76. Ali SM, Brodell RT, Balkrishnan R, Feldman SR. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol. 2007;143:912–5.

    Article  PubMed  Google Scholar 

  77. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl. 4):9–14.

    Article  PubMed  Google Scholar 

  78. Richards HL, Fortune DG, Griffiths CE. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006;20:370–9.

    CAS  Article  PubMed  Google Scholar 

  79. Feldman SR, Horn EJ, Balkrishnan R, Basra MK, Finlay AY, McCoy D, et al. International Psoriasis Council. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59:1009–16.

    Article  PubMed  Google Scholar 

  80. Feldman SR, Vrijens B, Gieler U, Piaserico S, Puig L, van de Kerkhof P. Treatment adherence intervention studies in dermatology and guidance on how to support adherence. Am J Clin Dermatol. 2017;18(2):253–71. https://doi.org/10.1007/s40257-017-0253-5. Review

    Article  PubMed  Google Scholar 

  81. Storm A, Andersen SE, Benfeldt E, Serup J. A prospective study of patient adherence to topical treatments: 95% of patients underdose. J Am Acad Dermatol. 2008;59:975–80.

    Article  PubMed  Google Scholar 

  82. Van De Kerkhof PC, De Hoop D, De Korte J, Cobelens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200:292–8.

    Article  PubMed  Google Scholar 

  83. Uhlenhake EE, Kurkowski D, Feldman SR. Conversations on psoriasis—what patients want and what physicians can provide: a qualitative look at patient and physician expectations. J Dermatolog Treat. 2010;21:6–12.

    Article  PubMed  Google Scholar 

  84. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296(14):1735–41.

    CAS  Article  PubMed  Google Scholar 

  85. Kimball AB, Gladman D, Gelfand JM, Gordon K, Horn EJ, Korman NJ, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–42. https://doi.org/10.1016/j.jaad.2008.01.006.

    Article  PubMed  PubMed Central  Google Scholar 

  86. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55(5):829–35.

    Article  PubMed  Google Scholar 

  87. Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493–9.

    Article  PubMed  Google Scholar 

  88. Husted JA, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res. 2011;63(12):1729–35.

    Article  Google Scholar 

  89. Wong K, Gladman DD, Husted J, Long JA, Farewell VT. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum. 1997;40:1868–72.

    CAS  Article  PubMed  Google Scholar 

  90. Wu JJ, Poon KY, Channual JC, Shen AY. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–50.

    CAS  Article  PubMed  Google Scholar 

  91. Wu JJ, Guérin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate. J Am Acad Dermatol. 2017;76(1):81–90. https://doi.org/10.1016/j.jaad.2016.07.042.

    CAS  Article  PubMed  Google Scholar 

  92. Reddy S, Wu JJ. The impact of tumor necrosis factor inhibitor therapy for psoriasis on cardiovascular risk. J Drugs Dermatol. 2016;15(8):1031–2.

    PubMed  Google Scholar 

  93. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.

    CAS  Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Andrea L. Neimann.

Ethics declarations

Conflict of Interest

Dr. Neimann reports personal fees and a role on the advisory board for Abbvie; grant, personal fees, non-financial support, a role on the advisory board, clinical trial fellowship support, and research study for Janssen; grant, clinical trial fellowship support, and research study for Amgen; and research studies for Gelgene and Pfizer, outside the submitted work.

Dr. Reddy reports personal fees, non-financial support, and consulting fee for Abbvie and personal fees, non-financial support, and research study for Novartis.

Drs. Soleymani and Cohen declare that they have nothing to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Psoriatic Arthritis

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Soleymani, T., Reddy, S.M., Cohen, J.M. et al. Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology–Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients. Curr Rheumatol Rep 20, 1 (2018). https://doi.org/10.1007/s11926-017-0706-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11926-017-0706-0

Keywords

  • Psoriasis
  • Psoriatic arthritis
  • PsA
  • Methotrexate
  • Biologics
  • Rheumatology
  • Dermatology